Moderna Stock Surges 145% Today, How High Can MRNA Go?

Biotech company Moderna (MRNA) has issued a promising update Wednesday, revealing that its cancer vaccine shows signs of preventing melanoma from spreading. The news sparked a significant rally for MRNA stock by as much as 145%, far exceeding other stocks on the market.

According to Moderna, a personalized mRNA cancer vaccine reduced the ​risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent the drugmaker’s ‌shares surging as much as 160%. Moderna developed the vaccine with Merck and tested it together with immunotherapy drug Keytruda, a widely used treatment for melanoma. Thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit as soon as next year if regulators approve the vaccine, Moderna President Stephen Hoge said in an interview.

… Continue reading the full article at the original source below.